SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience

ACROSTUDY is an open-label, non-interventional post-authorization safety study (PASS) that began in 2004 to evaluate safety in at least 1000 acromegaly patients treated for 5 years with the GH receptor antagonist pegvisomant (PEGV).  This commitment was fulfilled in 2013 but ACROSTUDY was e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Wajnrajch, Michael, Gomez, Roy, Hey-Hadavi, Judith, Kelepouris, Nicky, van der Lans, Joli, Camacho-Hubner, Cecilia, Cara, Jose, Rajicic, Natasa, Rao Valluri, Srinivas, Fleseriu, Maria, Salvatori, Roberto, Brue, Thierry, Ghigo, Ezio, Palladino, Andrew
Format: Artigo
Idioma:Inglês
Publicat: Endocrine Society 2019
Matèries:
Neuroendocrinology and Pituitary
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552861/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-LB079
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars